BIOMAT Database Logo BIOMAT Database Logo

[Pharmacological characterization of the new highly potent beta-adrenergic receptor blocker soquinolol]. 1988

J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Forschung und Entwicklung der Knoll AG, Ludwigshafen/Rhein.

The present pharmacological test results characterize soquinolol (5-[3-tertiary butylamino-2-hydroxypropoxy]-2-formyl-1,2,3,4- tetrahydroisoquinoline mucate, We 704, Sertum) as a highly potent non-subtype-selective beta-adrenergic receptor blocker, which is devoid of any intrinsic sympathomimetic activity. Its localanaesthetic activity (membrane stabilizing effect) is very weak. It also shows good enteral efficacy and long duration of action. In binding studies with heart (Ki beta 1 = 3.25 nmol/l) and lung membranes (Ki beta 2 = 0.85 nmol/l) its binding profile was found to be similar to that of propranolol. Soquinolol inhibits the isoprenaline-induced tachycardia (EC50% = 48 micrograms/l) in the guinea-pig Langendorff heart in vitro to the same degree as propranolol. However, in the conscious dog soquinolol's beta 1-adrenergic blocking activity (ED 50%) on intravenous injection (5.5 micrograms/kg) and oral administration (5.8 micrograms/kg) is about twice as great as that of pindolol and 19 times (i.v.) or 138 times (p.o.) greater than that of propranolol. These results suggest 95% enteral efficacy for soquinolol (pindolol 88%, propranolol 13%). The differences in soquinolol's and propranolol's efficacy detected in vitro and in vivo are partially attributable to differences in their kinetic properties namely the lower protein binding and the higher distribution volume of soquinolol. In the conscious dog, soquinolol inhibits beta 1-(ED 50% = 4.0 micrograms/kg) and beta 2-receptors (ED 50% = 2.7 micrograms/kg) at dose levels which do not differ significantly.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007545 Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. Isoprenaline,Isopropylarterenol,4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol,Euspiran,Isadrin,Isadrine,Isopropyl Noradrenaline,Isopropylnoradrenaline,Isopropylnorepinephrine,Isoproterenol Hydrochloride,Isoproterenol Sulfate,Isuprel,Izadrin,Norisodrine,Novodrin,Hydrochloride, Isoproterenol,Noradrenaline, Isopropyl,Sulfate, Isoproterenol
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D010869 Pindolol A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) Prindolol,LB-46,Visken,LB 46,LB46
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic

Related Publications

J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
[Beta-adrenergic receptor blocker poisoning].
January 2007, Medicina (Kaunas, Lithuania),
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
An irreversible blocker for the beta-adrenergic receptor.
March 1976, Biochemical and biophysical research communications,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
October 2009, Journal of the American College of Cardiology,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Synthetic and endogenous beta-adrenergic receptor antagonists--comparative pharmacological characterization.
June 2009, Autonomic neuroscience : basic & clinical,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Characterization of a new, highly specific, beta 3-adrenergic receptor radioligand, [3H]SB 206606.
August 1994, Molecular pharmacology,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists.
February 1973, Life sciences. Pt. 1: Physiology and pharmacology,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Some pharmacological properties of a new adrenergic beta-receptor antagonist.
October 1966, Nature,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Molecular cloning and pharmacological characterization of the bovine beta 3-adrenergic receptor.
May 1995, European journal of biochemistry,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Labetalol: an alpha- and beta-adrenergic receptor blocker.
July 1985, The Nurse practitioner,
J Gries, and L Unger, and H Einig, and L Friedrich, and H P Hofmann, and H Kreiskott, and H D Lehmann, and G von Philipsborn, and D Wuppermann, and F Zimmermann
Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists.
August 1965, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!